Market Overview

Forty Seven Wins Exclusive License Deal For 5F9


Forty Seven (NASDAQ: FTSV) and Ono Pharmaceutical have inked an exclusive license agreement for the development, manufacture and commercialization of 5F9, Forty Seven’s monoclonal antibody against CD47.

The agreement includes all therapeutic uses of 5F9 as a monotherapy or combination agent in Japan, South Korea, Taiwan and the ASEAN countries.

Forty Seven is a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer. The company will retain all rights to 5F9 in the rest of the world including the US, Europe, and China.

Forty Seven shares are trading down 0.8% at $10.17 Thursday morning. The stock has a 52-week high of $23.83 and a 52-week low of $9.90.

Related Links:

Ohr Pharmaceutical Merger With Neubase Therapeutics Approved By Shareholders

Can-Fite BioPharma Appeals Lawsuit Against Venture Capital Firm

Posted-In: News


Related Articles (FTSV)

View Comments and Join the Discussion!
Lightning Fast
Market News Service
$199 Free 14 Day Trial

Cemtrex To Develop Augmented Reality Experience For 7 Luxury Brands

Willis Towers Watson Poised For Guidance Raise, Wells Fargo Says In Upgrade